View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Heineken: No respite / IBA: Attractive €15-20m acquisition in radio pharma.

Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Michiel Declercq
  • Thibault Leneeuw
  • Wim Lewi

Morning Notes : BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, N...

: BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, NXFIL NA, ENRGY BB

 PRESS RELEASE

IBA acquires ORA expanding its strategic leadership in Nuclear Medicin...

IBA acquires ORA expanding its strategic leadership in Nuclear Medicine Louvain-La-Neuve, Belgium, 19 December 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires ORA, a global trailblazer in radiochemistry based in Belgium. This acquisition emphasizes IBA’s long-term commitment to the fast-developing and promising field of nuclear medicine. It reinforces IBA’s position at the forefront of innovation in precision oncology enabling for better diagnostic and more personalized patient...

 PRESS RELEASE

Avec l’acquisition d’ORA, IBA renforce son leadership stratégique en m...

Avec l’acquisition d’ORA, IBA renforce son leadership stratégique en médecine nucléaire Louvain-la-Neuve, Belgique, le 19 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et acteur de premier plan en médecine nucléaire, acquiert ORA, pionnier mondial de la radiochimie, basé en Belgique. Cette acquisition illustre l'engagement à long terme d'IBA dans le domaine en pleine expansion et à fort potentiel de la médecine nucléaire. Elle consolide la position d'IBA à l’avant-garde de l'innovation en oncologie de précision, p...

 PRESS RELEASE

Solvay Financial Calendar 2026

Solvay Financial Calendar 2026 Press release                                                                  Regulated information Brussels, December 17, 2025, 5.45pm CET Solvay today publishes its 2026 financial calendar. EventDateInterim dividend: ex-dateJanuary 19, 2026Interim dividend: payment dateJanuary 21, 2026Fourth quarter and full year 2025 earnings February 24, 2026First quarter 2026 earnings May 7, 2026Ordinary General Shareholders’ MeetingMay 12, 2026Second quarter and first half year 2026 earnings July 29, 2026Third quarter and first nine months 2026 earnings November 4, 20...

 PRESS RELEASE

Calendrier financier de Solvay en 2026

Calendrier financier de Solvay en 2026 Communiqué de presse                                                                 Information réglementée Bruxelles, le 17 décembre 2025 - 17h45 CET Solvay publie aujourd’hui son calendrier financier pour 2026. ÉvénementDateDividende intérimaire: ex-date19 janvier 2026Dividende intérimaire: date de paiement21 janvier 2026Résultats du quatrième trimestre et de l’année 202524 février 2026Résultats du premier trimestre 20267 mai 2026Assemblée générale ordinaire des actionnaires12 mai 2026Résultats du deuxième trimestre et du premier semestre 202629 j...

 PRESS RELEASE

Financiële kalender van Solvay in 2026

Financiële kalender van Solvay in 2026 Persbericht                                                             Gereglementeerde informatie Brussel, 17 december 2025, 17u45 CET Solvay publiceert vandaag zijn financiële kalender voor 2026. Evenement Datum Interimdividend: ex-coupon datum 19 januari 2026 Interimdividend: datum van betaling 21 januari 2026 Resultaten voor het vierde kwartaal en jaar 2025 24 februari 2026 Resultaten eerste kwartaal 2026 7 mei 2026 Gewone algemene aandeelhoudersvergadering  12 mei 2026 Resultaten tweede kwartaal e...

Guy Sips ... (+2)
  • Guy Sips
  • Kristof Samoy
Kristof Samoy
  • Kristof Samoy

CMB.Tech Investment in Chinese ammonia supply

CMB.TECH is investing in the Chinese ammonia supply chain and signed an off-take agreement for green ammonia produced by CEEC in the Jilin Province and will own a minority share in privately owned Andefu, one of China's largest ammonia supply chain companies. While CMB.TECH did not disclose any financials on the deal we estimate linked financials are relatively small. CMB.TECH has a sensible but disciplined investment approach towards decarbonisation. Through the offtake agreement and terminal o...

 PRESS RELEASE

CMB.TECH INVESTS IN CHINESE AMMONIA SUPPLY

CMB.TECH INVESTS IN CHINESE AMMONIA SUPPLY Antwerp, Dec. 16, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMBT”, “CMB.TECH” or “the Company”) is pleased to announce the company is investing in the Chinese ammonia supply chain. CMB.TECH has signed an off-take agreement for green ammonia produced by CEEC Hydrogen Energy (“CEEC”) in Jilin Province and will own a minority share in privately owned Jiangsu Andefu Energy Technology Co., Ltd. (“Andefu”) one of China's largest ammonia supply chain companies. Green ammonia produced...

 PRESS RELEASE

Participation notification by UBS Group AG

Participation notification by UBS Group AG Press release                                                                  Regulated informationBrussels, December 15, 2025, 17:45 CET In line with Belgian transparency legislation (Law of May 2, 2007), UBS Group AG recently sent to Solvay the following transparency notification indicating that they crossed the threshold of 3%.  Here is a summary of the notification:  Voting rights after the transactionEquivalent financial instruments after the transactionTotalPrevious0.17%2.88%3.05%New0.17%3.20%3.37% The notification, dated December 10, 2025...

 PRESS RELEASE

Notification de participation par UBS Group AG

Notification de participation par UBS Group AG Communiqué de presse                                                                 Information réglementée Bruxelles, le 15 décembre 2025 - 17h45 CET Conformément à la législation et réglementation en matière de transparence financière (loi du 2 mai 2007), UBS Group AG a envoyé récemment à Solvay la notification de transparence suivante, indiquant avoir franchi le seuil de 3%.  Voici un résumé de la notification:   Droits de vote après la transaction Instruments financiers équivalents après la transaction Total...

 PRESS RELEASE

Participatiemelding van UBS Group AG

Participatiemelding van UBS Group AG Persbericht                                                                 Gereglementeerde informatie Brussel, 15 december 2025 - 17u45 CET In overeenstemming met de Belgische transparantiewetgeving (Wet van 2 mei 2007) heeft UBS Group AG onlangs de volgende transparantiekennisgeving naar Solvay gestuurd om aan te geven dat ze de drempel van 3% heeft overschreden.  Hier is een samenvatting van de beweging:   Stemrechten na de transactie Aan stemrechten gelijkgestelde financiële instrumenten na de transactie Totaal Vor...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

IBA: The Lancet Journal on proton therapy new standard of care for patients with Oropharyngeal cancer. Events Calendar

Hilde Van Boxstael ... (+7)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Michiel Declercq
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi
Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Thematic - 2026 Outlook - "5 More Years" (55pgs)

For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...

 PRESS RELEASE

Proton Therapy New Standard of Care for Patients with Oropharyngeal Ca...

Proton Therapy New Standard of Care for Patients with Oropharyngeal Cancer Louvain-La-Neuve, Belgium, December 15, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, is pleased to share today that, on December 11,  The Lancet – one of the world’s most renowned  academic journals – published a landmark study that recommends proton therapy as a new standard of care for patients with oropharyngeal cancer. , led by MD Anderson Cancer Center, the world’s ...

 PRESS RELEASE

La protonthérapie, nouvelle norme de soins pour les patients atteints ...

La protonthérapie, nouvelle norme de soins pour les patients atteints d'un cancer de l'oropharynx Louvain-la-Neuve, Belgique, le 15 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le traitement du cancer, a le plaisir d'annoncer aujourd'hui que The Lancet – l'une des revues scientifiques les plus renommées au monde – a publié, le 11 décembre, une étude historique recommandant la protonthérapie comme nouvelle norme de soins pour les patients atteints d'...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Belgian Telecoms: DIGI Belgium CEO Interview: ‘We are running a marathon, not a sprint' IBA: IBA to install a Rhodotron in East China. Ontex: Another quarter, another profit warning. Theon International: Backlog visibility indeed. Xior: 2026 outlook positive but with no major surprise. Events Calendar

Guy Sips ... (+9)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Wim Hoste
  • Wim Lewi

Morning Notes : ACKB BB, AKZA NA, IBAB BB, ONTEX BB, SEQUA BB, XIOR BB...

: ACKB BB, AKZA NA, IBAB BB, ONTEX BB, SEQUA BB, XIOR BB, DEME BB, ARG FP, ZEAL DC

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch